TY - GEN. T1 - Tensile and flexural creep behaviour of self-reinforced polypropylene composites prepared by compression and injection molding. AU - Kmetty, Á. AU - Bakonyi, P.. AU - Vas, M. L.. AU - Bárány, T.. PY - 2012. Y1 - 2012. N2 - In this work the creep behavior of self-reinforced polymer composites (SRPC) were investigated. As matrix material olefin based thermoplastic elastomeric (o-TPE), as reinforcement highly oriented polypropylenes were used. The tested self-reinforced composites were prepared by filament winding with subsequent compression molding and injection molding (from new pre-impregnated pre-product material) technique. On the SRPC creep tests were carried out. The tensile and flexural creep tests were performed by universal tensile machine and dynamic mechanical analyzer (DMA) test. The results revealed that the creep behavior of the self-reinforced materials depended on the matrix material and the reinforcement structure. The highest strain was achieved using woven ...
Endosteal fixation of a ligament graft with a bioabsorbable interference screw installed in a retrograde manner in ACL reconstruction. The bioabsorbable interference screw is insert-molded with a length of suture extending from the distal tip of the screw for pulling the interference screw into the joint and into position for retrograde insertion at the top of the tibial tunnel. The interference screw has a cannulation extending partially through the screw from the leading tip. The cannulation is shaped to receive a correspondingly shaped driver. The driver is inserted into the tibial tunnel to engage the screw. By turning the driver, the interference screw is turned into the tibial tunnel in a retrograde manner. Accordingly, interference fixation of the graft near the tibial plateau is provided, thereby eliminating graft abrasion at the tibial plateau tunnel opening.
This review discusses and summarizes the recent developments and advances in the use of biodegradable materials for bone repair purposes. The choice between using degradable and non-degradable devices for orthopedic and maxillofacial applications must be carefully weighed. Traditional biodegradable devices for osteosynthesis have been successful in low or mild load bearing applications. However, continuing research and recent developments in the field of material science has resulted in development of biomaterials with improved strength and mechanical properties. For this purpose, biodegradable materials, including polymers, ceramics and magnesium alloys have attracted much attention for osteologic repair and applications. The next generation of biodegradable materials would benefit from recent knowledge gained regarding cell material interactions, with better control of interfacing between the material and the surrounding bone tissue. The next generations of biodegradable materials for bone repair and
This is the first case in the literature describing the V-stenting technique using ABSORB (Abbott Vascular, Santa Clara, California) bioresorbable everolimus-eluting scaffolds (BVS) for the treatment of a left main coronary artery (LMCA) true bifurcation lesion. A 66-year-old woman presented with symptoms of stable angina. A diagnostic angiogram revealed a significant mid-left anterior descending artery (LAD) lesion. After successful implantation of 2 BVS in the mid-LAD, a control angiogram showed haziness extending from distal LMCA into LAD ostium (Medina 0.1.1), likely representing plaque disruption (Fig. 1-I). Due to the fact that the lesions extended in both the LAD and left circumflex artery, we decided to perform V-stenting. A 3.5 × 12-mm BVS (LMCA-LAD) and a 3.5 × 18-mm BVS (LMCA-left circumflex artery) were simultaneously deployed followed by final kissing-balloon inflation. An excellent final angiographic result was achieved (Fig. 1-III). Post-procedural intravascular ultrasound and ...
Plaster of Paris is employed to form implants as well as a bioresorbable scaffold for implants and bone repair in animals. In bone repair, the plaster is mixed with a non-bioresorbable calcium source,
Mountain View, Calif.-based Amaranth Medical announced a $20 million Series B funding round in support of development of the companys flagship Fortitude bioresorbable scaffold, a device-based treatment for coronary artery disease.. Amaranth plans to use the funds to further progress in clinical trials in hopes of winning CE Mark approval in the European Union, according to a company statement. ...
Ultrasonically Assisted Anchoring of Biodegradable Implants for Chevron Osteotomies - Clinical Evaluation of a Novel Fixation Method
The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
Scaffolds for tissue engineering prepared from biocompatible, biodegradable polymer-based, lighter than or light as water microcarriers and designed for cell culturing in vitro in a rotating bioreacto
Self-reinforced poly(ethylene terephthalate) composite laminates were manufactured from fabric using a hot press. Fabric was either allowed to shrink or exposed to stretching during different phases of the manufacturing process. Composite macrostructure, crimp, was investigated and results showed that shrinkage affects fibre crimp more than stretching does. Mechanical tests showed that shrinkage do not significantly affect mechanical properties while stretching fabric by 10% during heating results in 50% increase in tensile stiffness. The lack of correlation between crimp and mechanical properties indicates that mechanical properties for self-reinforced poly(ethylene terephthalate) composites are dominated by their microstructure, molecular orientation, which may be affected by the manufacturing process.. ...
BACKGROUND: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized.. METHODS: We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis.. RESULTS: BVS compared with cobalt-chromium everolimus-eluting stents resulted in higher 3-year rates of target lesion failure (11.7% versus 8.1%; risk ratio [RR], 1.38; 95% confidence interval [CI], 1.10-1.73; P=0.006), driven by greater target vessel myocardial ...
The absence of clinical restenosis in the first major trial of metallic drug-eluting stents (DES) (1) elicited unbridled enthusiasm among interventional cardiologists. However, it did not take long to realize that, although DES were a marked improvement over bare-metal stents (2), they were not perfect. Specifically, McFadden and et al. (3) reported a new complication in 4 patients, late stent thrombosis occurring after discontinuation of dual antiplatelet therapy (DAPT) (3). Since then, we have learned that target lesion-related failures after 1 year (including restenosis as well as thrombosis) occur at a frequency of 2% to 3% per year for all permanent metallic stents, a rate that may continue for 20 years or longer (4,5). The mechanisms contributing to these stent-related failures are multifactorial and include incomplete endothelialization, persistent inflammation, vessel straightening and compliance mismatch, strut fracture, neoatherosclerosis, and others. Bioresorbable vascular scaffolds ...
This is the first prospective study to evaluate the economic outcomes associated with the use of a bioresorbable scaffold versus a conventional DES among patients undergoing PCI. In this randomized trial involving 2,008 patients with stable and unstable coronary artery disease, we found that the use of the Absorb scaffold was associated with slightly higher procedural costs and index hospitalization costs when compared with the Xience stent. Although the total 1-year costs were also numerically higher in the Absorb group, the cost difference was small (approximately $350/patient) and was not significant. Taken together with clinical outcomes demonstrating statistical noninferiority of the Absorb scaffold to the Xience DES, these findings demonstrate roughly comparable clinical and economic outcomes with these 2 devices within 1 year (assuming a $100 per device price difference). However, these results remain uncertain at present, because the ABSORB III trial was underpowered to exclude small ...
TY - JOUR. T1 - Handedness of Twisted Lamella in Banded Spherulite of Chiral Polylactides and Their Blends. AU - Wang, Hsiao Fang. AU - Chiang, Chen Hung. AU - Hsu, Wen Chun. AU - Wen, Tao. AU - Chuang, Wei Tsung. AU - Lotz, Bernard. AU - Li, Ming Chia. AU - Ho, Rong Ming. PY - 2017/7/25. Y1 - 2017/7/25. N2 - Banded spherulite resulting from lamellar twisting due to the imbalanced stresses at opposite fold surfaces can be formed by isothermal crystallization of chiral polylactide and its blends with poly(ethylene glycol) (PEG). Using a polarized light microscope, the handedness of the twisted lamella in banded spherulite is determined. With the same growth axis along the radial direction as evidenced by wide-angle X-ray diffraction (WAXD) for isothermally crystallized samples at different temperatures, the twisted lamellae of chiral polylactides (poly(l-lactide) (PLLA) and poly(d-lactide) (PDLA)) display opposite handedness. The split-type Cotton effect on the C = O stretching motion of ...
Bioresorbable drug-eluting scaffolding appears to be safe and effective in patients with iliac and femoral artery lesions, based on six-month results in the first-in-man ESPRIT trial presented Jan. 22 at the International Symposium on Endovascular Therapy in Miami Beach, Fla.
The DESappear study is an important milestone in the pursuit of bringing innovative therapies with state-of-the-art bioresorbable technologies to treat a vulnerable population of patients with peripheral arterial disease," said Bosiers. "I am excited to be working with Akesys Medical with the goal to bring this vital product to the clinic.". DESappear investigator Andrew Holden, director of Interventional Services at Auckland City Hospital and associate professor of Radiology at Auckland University School of Medicine, implanted the first Prava in a 66-year-old patient with 45mm of disease in the mid-superficial femoral artery and 80% blockage.. "The diabetic patient with short distance leg claudication demonstrated 0% residual stenosis following the procedure with the Prava scaffold and has recovered well," said Holden. "The Prava scaffolds easy deliverability for treatment and its excellent structural support to the vessel without leaving behind a permanent metallic implant has the potential ...
Novel methods for assessing the electrochemical and micromechanical performance of modular tapers were evaluated, and self-reinforced composite materials were developed for their potential to prevent the onset of mechanically assisted corrosion in modular taper devices. A study of the seating and taper locking mechanics of modular taper samples was conducted, and the effect on taper engagement strength of seating load, loading rate, taper moisture, and taper design/material combination was studied. The load-displacement behavior was captured during seating, and the subsequent pull off load was correlated to seating displacement, seating energy, and seating load. The primary factor affecting taper engagement strength was seating load, and loading rate and design/material factors did not have a significant impact on the quality of the taper engagement. Next, the effect of variation of 7 different design, material, and surgical factors on the fretting corrosion and micromechanical behavior during
Vascular response after coronary angioplasty varies according to the technique. Acute response after balloon angioplasty is characterized by luminal gain in most cases, although dissection can occur during the procedure, putting coronary artery patency at risk. Arterial "elastic recoil" sometimes follows this acute luminal gain, resulting in some degree of restenosis.. Bare-metal stents represented a great advance because they overcame these 2 main limitations of balloon angioplasty. However, vascular damage created by bare-metal stent implantation can result in intense tissue proliferation around the struts, leading to another form of restenosis: proliferative rather than mechanical recoil. Drug-eluting stents (DES) were developed to overcome this limitation by incorporating antiproliferative drugs. First-generation DES changed the post-stenting healing process; however, the lack of coverage of a substantial amount of DES struts was shown to contribute substantially to stent thrombosis ...
Researchers for the DESolve study recommended testing the latest iteration of the device in a larger group of patients, based on results of a first-in-man-study published in the December issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.
Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy
To gain insight into the comparative clinical efficacy of the Orsiro bioabsorbable polymer stent versus an everolimus-eluting durable polymer stent ...
The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substant
Read "Supramolecular structure of polylactides: Influence of the crystallization parameters on the structure of film samples, Russian Journal of Applied Chemistry" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days). In dual target lesion setting, both lesions must meet clinical procedure success criteria to have a patient level procedure success.. Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population (PTE) analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only. ...
Wykrzykowska et al report a randomized clinical trial of metallic stent v bioresorbable vascular scaffold in routine percutaneous coronary intervention. They found significantly higher risk of device thrombosis with BVS. The editorial is available here. Summary BACKGROUND Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drugeluting stents in percutaneous coronary intervention (PCI). We…
While coronary stents have been used to treat CAD since the 1990s, a new stent technology - the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System - was approved by the U.S. Food and Drug Administration in October 2015, and is the first and only bioabsorbable polymer stent available in the U.S. Unlike traditional drug coated stents that feature permanent polymer coatings known to cause inflammation within the vessels, the SYNERGY stents coating dissolves and disappears after the stents drug has been released. This action enables quick healing of the blood vessel, leaving only the metal part of the stent in the body; ensuring that the blood vessel remains propped open and can deliver blood to the heart for life.. ...
- Clinical Results from 101 Patients Show Low MACE Rate, No Blood Clots and Low Late Loss - In a Sub-Analysis, Nearly All Patients Vessels Assessed for Vasomoto
Bioabsorbable vascular scaffolds are naturally dissolving scaffolds used in the treatment of coronary artery disease (CAD). These are the latest...
In medicine, a stent is any device which is inserted into a blood vessel or other internal duct in order to expand the vessel to prevent or alleviate a blockage. Traditionally, such devices are fabricated from metal mesh and remain in the body permanently or until removed through further surgical intervention. A bioresorbable stent, (also called biodegradable, or naturally-dissolving) serves the same purpose, but is manufactured from a material that may dissolve or be absorbed in the body. The use of metal drug-eluting stents presents some potential drawbacks. These include a predisposition to late stent thrombosis, prevention of late vessel adaptive or expansive remodeling, hindrance of surgical revascularization, and impairment of imaging with multislice CT. To overcome some of these potential drawbacks, several companies are pursuing the development of bioresorbable or bioabsorbable stents. Like metal stents, placement of a bioresorbable stent will restore blood flow and support the vessel ...
Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best option for percutaneous coronary interventions (PCI) based revascularization. However, despite their optimal performance, a few concerns remain regarding their use, mainly due to permanent caging of the vessels and its consequences, first of all late stent thrombosis (ST). Bioresorbable scaffolds (BRS) aim to overcome these issues. The results achieved in randomized controlled trials (RCT) by the first generation of poly-L-lactic acid (PLLA) based scaffolds were promising at 1 year, but the first long term reports (albeit flawed by non-optimal implantation technique) have been disappointing, showing, for instance, an increased risk of ST and target vessel myocardial infarction (TV-MI ...
Summary. GlobalDatas Medical Devices sector report, Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015″ provides an overview of Bioabsorbable Stents currently in pipeline stage.. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.. Browse Full Report With TOC at ...
Summary. GlobalDatas Medical Devices sector report, Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015″ provides an overview of Bioabsorbable Stents currently in pipeline stage.. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.. Browse Full Report With TOC at ...
A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a biabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm 3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic
The hose of the present invention comprises an all plastic multilayer hose having a reinforcement therein which is of a material which is flexible and stiff under normal working conditions and which has a flow temperature less than the flow temperature of the cover and liner layers and which forms spaced reinforcing elements incident to the manufacture of the hose. The present invention contemplates use of an apparatus and simplified method which permits the reinforced hose to be readily manufactured in predetermined lengths or continuously so as to provide a hose of indefinite lengths.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts. ...
Results In total 100 patients underwent PCI with a SYNERGY during the one-year study period. The mean age was 72.3 years (10.0; range 41-92 years), 37% of the cohort was defined as elderly (age ,75 years) and 8% defined as very elderly (age ,85 years). Mean EuroSCORE was 11.37 (11.13, range 0.88-70.23). The indication for SYNERGY stent use was as follows; frail or elderly (16%), concurrent anticoagulation (28%) need for a non-cardiac procedure (10%), increased bleeding risk (31%), or other (15%). NSTEMI/STEMI was the presenting complaint in 32% of patients. The coronary disease was complex. Left main stem was involved in (13%), multi-vessel disease (36%), bifurcation disease requiring side-branch stenting (9%), and 37% required CTO intervention. Mean Syntax score was 22.7 (12.1, range 6-53). The mean stent length/ patient was 75.3 mm (41.5) with 1.44 (0.64) lesions treated and 2.67 (1.33) stents implanted per patient. DAPT discontinuation by 3 months has occurred in 52% to date (planned in ...
There is an ongoing clinical need for tissue-engineered small-diameter (,6 mm) vascular grafts since clinical applications are restricted by the limited availability of autologous living grafts or the lack of suitability of synthetic grafts. The present study uses our self-assembly approach to produce a fibroblast-derived decellularized vascular scaffold that can then be available off-the-shelf. Briefly, scaffolds were produced using human dermal fibroblasts sheets rolled around a mandrel, maintained in culture to allow for the formation of cohesive and three-dimensional tubular constructs, and then decellularized by immersion in deionized water. Constructs were then endothelialized and perfused for 1 week in an appropriate bioreactor. Mechanical testing results showed that the decellularization process did not influence the resistance of the tissue and an increase in ultimate tensile strength was observed following the perfusion of the construct in the bioreactor. These fibroblast-derived ...
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections. This search facility features: flexible search syntax; automatic word stemming and relevance ranking; as well as graphical results.
Barchart.com Inc. is the leading provider of real-time or delayed intraday stock and commodities charts and quotes. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis.
Future Market Insights on Global Bioabsorbable Stents Market Future Market Insights recently published a fully researched publication on "Global Bioabsorbable Stents Market: Industry analysis (2012-2016) and Opportunity Analysis (2017-2022)", which...
The FDA does not approve of any food item or drug until it has verified everything regarding its safety for human consumption. Today, it has given the go-ahead signal for the first-ever absorbable stent. It will come in handy in the treatment of coronary artery disease.. Get the Free Tracker App to find a Luvabella in Stock. Termed the Absorb GT1 Bioresorbable Vascular Scaffold System (BVS), it gives off the drug everolimus which retards the formation of scar tissue. Also the stent is absorbed by the body slowly and steadily over the course of three years. This approval by the FDA is of great significance since the absorbable stent is a novel treatment method for people who are ideal candidates for angioplasty.. The fact that the stent is absorbable means that those individuals who fear the interventionist scheme of having a foreign metal stent in their bodies would prefer this new method of prophylaxis.. Coronary heart disease (CHD) claims as many as 370,000 lives every year in the United ...
BARCELONA, Spain, May 20, 2009 - Six months outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success rate (> 97%), and sustained safety.. Presented by Dr. Ricardo A. Costa, of Cardiovascular Research Center, Brazil, Preliminary clinical results at 6 months (60%) from Multicenter E-Series Registry demonstrate clinical effectiveness of Supralimus in preventing revascularization, with only 2% TVR (Target Vessel Revascularization) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patients in-Hospital. The stent thrombosis rate (definite/probable, ARC) up to 6 months was less than 1%.. Out-of Hospital adverse events (N=718) included only 2% Cardiac Death, 0.5% MI (Myocardial ...
This study is investigating the effect of everolimus drug-eluting stent [Xience Prime] versus everolimus bioresorbable vascular scaffold [Absorb] on vasomotor
PURPOSE: The use of bioabsorbable self-reinforced poly(L/DL)lactide 70/30 (SR-PLDLA) miniplates and screws could offer many benefits compared with conventional metallic devices for fixation of access osteotomies in oral cancer surgery. The material neither interferes with imaging nor with postoperative radiotherapy. The plates and screws do not need to be removed ...
Resorbable materials and their preparation based on gelling a solution of a single polylactide enantiomer. The gel may be dried to produce solid materials, or may be extracted with a nonsolvent prior to drying to make microporous materials. Physical and mechanical properties of the material may be varied by varying the molecular weight of the gelling polymer, or by blending the gelling solution with other polymers or fillers. The resorbable materials can be used to make biodegradable implantation devices.
DSI Syntoss Resorbable Collagen Membrane, used in oral surgery and periodontal surgery to prevent epithelium growth. Easy to trim, shape and adapt.
12-month data from the RESTORE pilot clinical trial between December 2011 and July 2012 were also presented at TCT. The RESTORE trial was designed to evaluate safety and performance of the first generation ReZolve sirolimus-eluting bioresorbable coronary scaffold. Imaging results of patients treated with ReZolve who remained event free after treatment demonstrated a mean in-stent late loss of 0.29 mm. When imaging results for patients who had undergone retreatment for focal in-stent restenosis the mean in-stent late loss was 0.69 mm ...
The goal of this project is to investigate antibacterial property and biocompatibility of a new class of bioresorbable alloys for musculoskeletal repair and rec...